BACKGROUND Anticoagulation for mechanical heart valves during pregnancy is essential to prevent thromboembolic
Vitamin K antagonists (VKAs), such as warfarin, are effective at reducing thromboembolic events and are standard therapy for anticoagulation in the absence of contraindications (2) . However, several studies have demonstrated teratogenicity of warfarin during the sixth to ninth weeks of pregnancy (3) (4) (5) , and some studies have found a high rate of fetal loss in pregnant women taking warfarin (6) . Therefore, many patients and physicians have been reluctant to use a VKA during pregnancy, despite guidelines in the United States and Europe that recommend it for many patients during pregnancy (7, 8) .
There has never been a randomized trial comparing different anticoagulation regimens in pregnant women with MHVs, and current guidelines are largely devised on the basis of case series and expert consensus. The most widely cited systematic review (6) was written before the use of low-molecularweight heparin (LMWH) and included many patients with older-generation ball-in-cage valves, thereby limiting the relevance of this review in contemporary patients. Subsequent systematic reviews and metaanalyses have included women on fixed-dose LMWH, which is now known to be associated with catastrophic valve failure (9, 10) .
The goal of this meta-analysis was to estimate the risk of adverse maternal and fetal outcomes among different anticoagulation regimens in a contemporary population of pregnant women with modern MHVs. valves; if fixed doses of either UFH or LMWH were administered; if <5 pregnancies were reported; if pregnancies either were not followed to term or the reported anticoagulation regimen was initiated after the first trimester; if results had previously been published; or if studies were published in a language other than English. Studies reporting outcomes in individuals with mechanical tricuspid or pulmonic valves, in which right-sided valve dysfunction was not specifically reported on, were also excluded out of concern that these valves are at a higher risk for thrombosis and dysfunction (11) (12) (13) (14) (15) that could skew the study results. Attempts were made to include all studies reporting on left-sided MHVs. Results from studies reporting outcomes from both right-and leftsided MHVs, in which valve dysfunction was clearly identified as right sided or left sided, were included.
If, however, the position of the dysfunctional valve could not be discerned, the study was excluded. Investigators of each study that met inclusion criteria were contacted if additional data were required.
Four anticoagulation regimens were included in this meta-analysis: 1) VKAs continued throughout the entirety of pregnancy (VKA); 2) dose-adjusted LMWH for the entirety of pregnancy (LMWH); 3) doseadjusted LMWH for the first trimester, followed by a VKA for the remainder (LMWH and VKA); and 4) doseadjusted UFH for the first trimester, followed by a VKA for the remainder (UFH and VKA). We also identified women who received low-dose warfarin, defined as #5 mg of daily warfarin in individuals able to maintain a therapeutic international normalized ratio (INR). Steinberg et al.
Anticoagulation in Pregnant Women With Mechanical Heart Valves J U N E 6 , 2 0 1 7 : 2 6 8 1 -9 1 study. The occurrence of a congenital defect was defined as warfarin embryopathy or any unexpected congenital anomaly for gestational age (excluding patent ductus arteriosus in premature infants). All analyses were carried out using the statistical software R (R Project for Statistical Computing, Vienna, Austria) (38), and the meta-regression model was fitted using the metafor package (39) . We used restricted maximum likelihood for the estimation of the between-cohort variance.
RESULTS
Of the 825 publications identified through the Medline search, 579 were on an unrelated topic, 92 did not include primary patient-related data (e.g., review papers, editorials), and 137 met the exclusion criteria Data on the percentage of pregnant women with ball-in-cage valves were missing in 6 studies. Of these, only 1 study included pregnancies before 1998
and accounted for 6% of the total VKA cohort (28).
The majority of published outcomes for the VKA, UFH and VKA, and low-dose warfarin regimens originated from Asia, Africa, and the Middle East (85%, 90%, and 76% of pregnancies, respectively). Most published outcomes for the LMWH regimen originated from Europe and North America (79%). Most published outcomes for the LMWH and VKA regimen originated from a multinational study (72%); however, the Figure 1 . Steinberg et al.
Anticoagulation in Pregnant Women With Mechanical Heart Valves
J U N E 6 , 2 0 1 7 : 2 6 8 1 -9 1 investigators reported that most patients with this regimen were treated in developed countries (33).
The study-specific risks of the composite maternal and fetal outcomes are reported in forest plots (Figures 2 and 3 95% CI: 0.9 to 8.8) (Figure 4) . The number of reported maternal deaths was low across all regimens, and consequently, the incidence of systemic thromboembolism and/or valve failure was largely responsible for the observed differences among groups. Abbreviations as in Figures 1 and 2 . Table 2 ).
A significant amount of heterogeneity was present in the estimates of risk among studies. Heterogeneity was estimated to account for 44% (95% CI: 18% to 82%) of the variability of the averaged risk estimates of the maternal composite outcome and for 81% (95% CI: 67% to 90%) of the total variability of the averaged risk estimates of the fetal composite outcome, as displayed by the statistic I 2 (Online Tables 3 and 4) .
DISCUSSION
On the basis of this contemporary meta-analysis of 800 pregnancies in women with MHVs and modern anticoagulation regimens, VKA is the anticoagulation regimen associated with the lowest risk of adverse maternal outcomes. This finding is consistent with those of previous publications (6,9,10), despite the differences in the patients studied; we included many fewer women with ball-in-cage valves and included a study group of women taking dose-adjusted LMWH.
The risk of adverse maternal outcomes with doseadjusted LMWH throughout pregnancy is higher than that of a VKA regimen. This is balanced by a significant reduction in adverse fetal outcomes.
However, on comparison with a subset of individuals who continued taking #5 mg of warfarin throughout the duration of pregnancy, no significant difference in fetal risk was observed, thus supporting the notion that warfarin's teratogenic effects are dose dependent (42). Although the risk of maternal thromboembolic complications remains a concern with LMWH, we report a lower incidence of this complication, compared with previously published metaanalyses (9,10). The exclusion of fixed-dose LMWH regimens likely accounts for this difference and further strengthens the argument for the use of doseadjusted LMWH with anti-factor Xa levels during pregnancy. The use of a regimen of LMWH and VKA was not observed to have a lower risk of adverse maternal outcomes, compared with an LMWH regimen, despite the use of a VKA for the majority of each pregnancy. Our data lack granularity with regard to the trimester in which the majority of adverse maternal events occurred, but a possible explanation is that the risk of thrombosis is highest in the first trimester of pregnancy, when VKA risk to the fetus is highest. This could also explain the high incidence of adverse maternal outcomes observed with a regimen of UFH and VKA. It is notable that although the use of a VKA was associated with a high incidence of spontaneous abortion, the incidence of fetal death was quite low, a finding supporting the idea that fetal risk to VKA exposure is highest during early gestation (4).
It is also important to recognize that the relative reduction in adverse fetal outcomes with these regimens, compared with VKA, is likely to be signifi- Additionally, heterogeneity was greatest for the composite fetal outcome, which was largely driven by the incidence of spontaneous abortions. One explanation for this finding is the apparent dosedependent effects of VKAs on the developing fetus.
It is possible that differences in the distribution of VKA doses among studies were responsible for much of the observed heterogeneity. This illustration depicts maternal and fetal risk with different anticoagulation regimens. Maternal risk is lowest on a vitamin K antagonist (VKA) regimen, and fetal risk is lowest on a low-molecular-weight heparin (LMWH) regimen. The risk of either a maternal or fetal complication during pregnancy is lowest with a low-dose warfarin regimen; however, even low-dose warfarin carries a substantial risk of a poor outcome. CI ¼ confidence interval. meta-regression. The random effects analysis allowed us to account and quantify the heterogeneity among the estimates from the different studies; however, as a result, studies were weighted more uniformly in the analysis. Consequently, smaller, less-precise studies may have had a greater impact on the study results.
As such, we performed an analysis using a fixedeffects model to estimate maternal and fetal risk.
Similar results were obtained, with the exception that fetal risk in women receiving LMWH and VKA was 8%, one-half of what was estimated using the random effects model. This finding has little impact on our study conclusions and further supports the notion that avoidance of VKAs in the first trimester of pregnancy improves fetal risk.
Despite these limitations, we believe that reporting these data is important to clinical practice because no randomized data currently exist and randomized trials are unlikely, given the complex ethical and social issues involved in choosing an anticoagulation regimen for pregnant women. Therefore, our intention is to consolidate all contemporary primary data relating to this subject, so that practitioners and patients alike gain a greater understanding of the strength of the data that are the basis for current recommendations.
Our meta-analysis consolidates the current experience with up-to-date anticoagulant regimens in contemporary study patients with modern MHVs. 
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